Examinando por Autor "Torres-Macho, Juan"

Mostrando 1 - 4 de 4

Clustering analysis reveals different profiles associating long-term post-COVID symptoms, COVID-19 symptoms at hospital admission and previous medical co-morbidities in previously hospitalized COVID-19 survivors
(Springer, 2022) Fernández-de-las-Peñas, César; Martín-Guerrero, José D.; Florencio, Lidiane L.; Navarro-Pardo, Esperanza; Rodríguez-Jiménez, Jorge; Torres-Macho, Juan; Pellicer-Valero, Oscar J.
Purpose To identify subgroups of COVID-19 survivors exhibiting long-term post-COVID symptoms according to clinical/ hospitalization data by using cluster analysis in order to foresee the illness progress and facilitate subsequent prognosis. Methods Age, gender, height, weight, pre-existing medical comorbidities, Internal Care Unit (ICU) admission, days at hospital, and presence of COVID-19 symptoms at hospital admission were collected from hospital records in a sample of patients recovered from COVID-19 at fve hospitals in Madrid (Spain). A predefned list of post-COVID symptoms was systematically assessed a mean of 8.4 months (SD 15.5) after hospital discharge. Anxiety/depressive levels and sleep quality were assessed with the Hospital Anxiety and Depression Scale and Pittsburgh Sleep Quality Index, respectively. Cluster analysis was used to identify groupings of COVID-19 patients without introducing any previous assumptions, yielding three diferent clusters associating post-COVID symptoms with acute COVID-19 symptoms at hospital admission. Results Cluster 2 grouped subjects with lower prevalence of medical co-morbidities, lower number of COVID-19 symptoms at hospital admission, lower number of post-COVID symptoms, and almost no limitations with daily living activities when compared to the others. In contrast, individuals in cluster 0 and 1 exhibited higher number of pre-existing medical co-morbidities, higher number of COVID-19 symptoms at hospital admission, higher number of long-term post-COVID symptoms (particularly fatigue, dyspnea and pain), more limitations on daily living activities, higher anxiety and depressive levels, and worse sleep quality than those in cluster 2. Conclusions The identifed subgrouping may refect diferent mechanisms which should be considered in therapeutic interventions.
Effect of platelet rich plasma on sinus lifting: A randomized controlled clinical trial
(2011-12-02) Torres, Jesús; Tamimi, Faleh; Martínez, Pedro Pablo; Alkhraisat, Mohammad; Linares, Rafael; Hernandez, Gonzalo; Torres-Macho, Juan; López-Cabarcos, Enrique
6 7 Objective: The combination of anorganic bovine bone (ABB) with platelet rich plasma ABSTRACT 8 (PRP) has been widely used in bone regeneration procedures although its benefits are 9 10 11 12 13 14 15 16 17 18 19 20 a histology level and any adjunctive effects, we performed an ancillary study in 5 still unclear. The purpose of this study was to evaluate whether or not PRP improves the efficacy of ABB in sinus floor augmentation. In addition, we have investigated the effect of residual bone height and tobacco on implant survival in sinus augmentation procedures. Materials and Methods: 87 patients recruited for this study underwent 144 sinus floor augmentation procedures using ABB alone or ABB plus PRP (ABB+PRP) in a randomized clinical trial. A total of 286 implants were placed in the augmented bone, and their evolution was followed up for a period of 24 months. In order to investigate on 21 edentulous patients with symmetrical severely resorbed maxilla. In these patients, a 22 23 24 25 26 27 Results: Overall, 96.2% of ABB and 98.6% of ABB+PRP implant success was 28 bilateral sinus augmentation was randomly performed using ABB or ABB+PRP in a split-mouth design, and after 6 months, bone biopsies were taken from the implant sites for histological and histomorphometric analysis. obtained during the monitoring period and differences were not found between sites grafted with and without PRP in the 87 patients studied. Densitometry assessments and graft resorption were similar in both experimental groups. However, the histological and histomorphometrical analysis in the 5 edentulous patients revealed that bone 29 30 31 32 33 augmentation was significantly higher in sites treated with ABB+PRP (p¿0.05). 34 Another outcome from our study is that the lack of initial bone support (p¿0.05) and smoking (p=0.05) appeared to have a negative effect on the treatment success, that was accentuated when both circumstances coincided. 35 36 37 38 39 40 procedures. However, this study revealed that PRP can improve the osteoconductive 41 Conclusions: PRP is not a determining factor for implant survival in sinus lifting properties of ABB by increasing the volume of new bone formed. Moreover, in sinus augmentation procedures implant¿s survival rate seems more influenced by the residual bone height or by tobacco than by the type of bone graft. 42 43 44
Headache as a COVID-19 onset symptom and post-COVID-19 symptom in hospitalized COVID-19 survivors infected with the Wuhan, Alpha, or Delta SARS-CoV-2 variants
(Wiley, 2022) Fernández-de-las-Peñas, César; Cuadrado, Maria L.; Gómez-Mayordomo, Victor; Torres-Macho, Juan; Pellicer-Valero, Oscar J.; Martín-Guerrero, José D.; Arendt-Nielsen, Lars
ObjectiveThis study looked at differences in the presence of headache as an onset symptom of coronavirus disease 2019 (COVID-19) and as a post-COVID-19 symptom in individuals previously hospitalized owing to infection with the Wuhan, Alpha, or Delta variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).BackgroundHeadache can be present in up to 50% of individuals during the acute phase of SARS-CoV-2 infection and in 10% of subjects during the post-COVID-19 phase. There are no data on differences in the occurrence of headache in the acute- and post-COVID-19 phase according to the SARS-CoV-2 variants.MethodsA cross-sectional cohort study was conducted. Unvaccinated subjects previously hospitalized for COVID-19 caused by the Wuhan (n = 201), Alpha (n = 211), or Delta (n = 202) SARS-CoV-2 variants were scheduled for a telephone interview 6 months after hospital discharge. Hospitalization data were collected from hospital medical records.ResultsThe presence of headache as a COVID-19 onset symptom at hospitalization was higher in subjects with the Delta variant (66/202, 32.7%) than in those infected with the Wuhan (42/201, 20.9%; odds ratio [OR] 1.83, 95% confidence interval [CI] 1.17–2.88) or Alpha (25/211, 11.8%; OR 3.61, 95% CI, 2.16–6.01) variants. The prevalence of post-COVID-19 headache 6 months after hospital discharge was higher in individuals infected with the Delta variant (26/202, 12.9%) than in those infected with the Wuhan (11/201, 5.5%; OR 2.52, 95% CI 1.22–5.31) or Alpha (eight of 211, 3.8%; OR 3.74, 95% CI 1.65–8.49) variants. The presence of headache as a COVID-19 onset symptom was associated with post-COVID-19 headache in subjects infected with the Wuhan (OR 7.75, 95% CI 2.15–27.93) and Delta variants (OR 2.78, 95% CI 1.20–6.42) but not with the Alpha variant (OR 2.60, 95% CI 0.49–13.69).ConclusionHeadache was a common symptom in both the acute- and post-COVID-19 phase in subjects infected with the Wuhan, Alpha, and Delta variants but mostly in those infected with the Delta variant.
Presence of SARS-CoV-2 RNA in COVID-19 survivors with post-COVID symptoms 2 years after hospitalization: The VIPER study
(Wiley, 2024-05-15) Fernández-de-las-Peñas, César; Torres-Macho, Juan; Ruiz-Ruigómez, Maria; Arrieta-Ortubay, Estibaliz; Rodríguez-Rebollo, Carolina; Akasbi-Moltalvo, Miriam; Pardo-Guimerá, Virginia; Ryan-Murua, Pablo; Lumbreras-Bermejo, Carlos; Pellicer-Valero, Oscar J.; Giordano, Rocco; Arendt-Nielsen, Lars; Franco-Moreno, Anabel
The SARS-CoV-2 VIrus PERsistence (VIPER) study investigated the presence of long-lasting SARS-CoV-2 RNA in plasma, stool, urine, and nasopharyngeal samples in COVID-19 survivors. The presence of SARS-CoV-2 RNA reverse transcription polymerase chain reactions (RT-PCR) were analyzed within plasma, stool, urine, and nasopharyngeal swab samples in COVID-19 survivors with post-COVID symptoms and a comparison group of COVID-19 survivors without post-COVID symptoms matched by age, sex, body mass index and vaccination status. Participants self-reported the presence of any post-COVID symptom (defined as a symptom that started no later than 3 months after the initial infection). Fifty-seven (57.9% women, age: 51.1, standard deviation [SD]: 10.4 years) previously hospitalized COVID-19 survivors with post-COVID symptoms and 55 (56.4% women, age: 50.0, SD: 12.8 years) matched individuals who had a past SARS-CoV-2 infection without post-COVID symptoms were evaluated 27 (SD 7.5) and 26 (SD 8.7) months after hospital discharge, respectively. The presence of SARS-CoV-2 RNA was identified in three nasopharyngeal samples of patients with post-COVID symptoms (5.2%) but not in plasma, stool, or urine samples. Thus, SARS-CoV-2 RNA was not identified in any sample of survivors without post-COVID symptoms. The most prevalent post-COVID symptoms consisted of fatigue (93%), dyspnea, and pain (both, 87.7%). This study did not find SARS-CoV-2 RNA in plasma, stool, or urine samples, 2 years after the infection. A prevalence of 5.2% of SARS-CoV-2 RNA in nasopharyngeal samples, suggesting a potential active or recent reinfection, was found in patients with post-COVID symptoms. These results do not support the association between SARS-CoV-2 RNA in plasma, stool, urine, or nasopharyngeal swab samples and post-COVID symptomatology in the recruited population